PriceTargets.com logo

DIAGNOS - ADK Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: C$1.50
  • Forecasted Upside: 383.87%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
C$0.31 As of 04/19/2024 06:22 PM ET
▲ +0.01 (3.33%)

This chart shows the closing price for ADK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New DIAGNOS Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADK

Analyst Price Target is C$1.50
▲ +383.87% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for DIAGNOS in the last 3 months. The average price target is C$1.50, with a high forecast of C$1.50 and a low forecast of C$1.50. The average price target represents a 383.87% upside from the last price of C$0.31.

This chart shows the closing price for ADK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in DIAGNOS. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/12/2023Echelon Wealth PartnersBoost TargetSpeculative BuyC$1.00 ➝ C$1.50
10/28/2021Echelon Wealth PartnersReiterated RatingSpeculative Buy
(Data available from 4/19/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
DIAGNOS logo
DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. DIAGNOS Inc. was founded in 1998 and is headquartered in Brossard, Canada.
Read More

Today's Range

Now: C$0.31
Low: C$0.31
High: C$0.32

50 Day Range

MA: C$0.28
Low: C$0.24
High: C$0.35

52 Week Range

Now: C$0.31
Low: C$0.23
High: C$0.59

Volume

36,000 shs

Average Volume

86,632 shs

Market Capitalization

C$23.49 million

P/E Ratio

N/A

Dividend Yield

0.29%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of DIAGNOS?

The following Wall Street sell-side analysts have issued reports on DIAGNOS in the last year: Echelon Wealth Partners.
View the latest analyst ratings for ADK.

What is the current price target for DIAGNOS?

1 Wall Street analysts have set twelve-month price targets for DIAGNOS in the last year. Their average twelve-month price target is C$1.50, suggesting a possible upside of 383.9%. Echelon Wealth Partners has the highest price target set, predicting ADK will reach C$1.50 in the next twelve months. Echelon Wealth Partners has the lowest price target set, forecasting a price of C$1.50 for DIAGNOS in the next year.
View the latest price targets for ADK.

What is the current consensus analyst rating for DIAGNOS?

DIAGNOS currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ADK will outperform the market and that investors should add to their positions of DIAGNOS.
View the latest ratings for ADK.

What other companies compete with DIAGNOS?

Other companies that are similar to DIAGNOS include CloudMD Software & Services, Reliq Health Technologies, Aurora Spine, Liberty Biopharma and Trilogy International Partners. Learn More about companies similar to DIAGNOS.

How do I contact DIAGNOS's investor relations team?

DIAGNOS's physical mailing address is 7005 Taschereau Blvd, Suite 340 Brossard, BROSSARD, QC J4Z 1A7, Canada. The company's listed phone number is +1-450-6788882. The official website for DIAGNOS is www.diagnos.ca. Learn More about contacing DIAGNOS investor relations.